Going for a “KDIP” in colorectal cancer treatment

• Published in: Clinical and translational discovery Vol. 2; no. 3
• Main Authors: Kaur, Jastrinjan, Soucek, Laura
• Format: Journal Article
• Language: English
• Published: Birtinya John Wiley & Sons, Inc 01.09.2022; Wiley
• Subjects: Cancer therapies; Colorectal cancer; Conflicts of interest; Design; Glioma; Liver; Metastasis; Peptides; Proteins; Signal transduction; Tumors
• ISSN: 2768-0622; 2768-0622
• DOI: 10.1002/ctd2.108

[...]they showed that despite a short half-life of 30.9 min in serum, intravenous administration of KDIP resulted in a significant, dose-dependent reduction of tumour growth in a syngeneic subcutaneous mouse model of KITENIN-overexpressing CT26 cells, but had little effect on non-overexpressing CT26 tumours. Furthermore, intravenous KDIP treatment also reduced liver colonisation by KITENIN-overexpressing CT26 cells in a hepatic metastasis model. [...]while shedding light on a novel aspect of KITENIN's biology and how homodimerization regulates its stability, the authors have shown this feature to be a novel actionable target for cancer intervention and designed a first tool, KDIP, to modulate it. First and foremost, in this study, the authors have shown the efficacy of KDIP in syngeneic mouse models alone, leaving the question of whether the same effect also applies to human tumours unanswered.